| [1] |
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
|
| [2] |
Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain -containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
|
| [3] |
Liu Q, Liu J, Lin B, et al. Novel biomarkers in membranous nephropathy [J]. Front Immunol, 2022, 13: 845767.
|
| [4] |
Ronco P, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens [J]. Curr Opin Nephrol Hypertens, 2021, 30(3): 287-293.
|
| [5] |
姜传学，李龙海，王建，等. 特发性膜性肾病患者血清抗PLA2R抗体和抗THSD7A抗体的表达及诊断价值[J]. 临床误诊误治，2021, 34(4): 76-81.
|
| [6] |
薛痕，龚仲琴，黄秋萍. 肾组织PLA2R及THSD7A双阳性的特发性膜性肾病2例并文献复习[J]. 中国中西医结合肾病杂志，2020, 21(10): 923-924, 944.
|
| [7] |
De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy [J]. J Am Soc Nephrol, 2017, 28(2): 421-430.
|
| [8] |
温丽颖，李绍梅，闫喆，等. M型磷脂酶A2受体及1型血小板反应蛋白7A域在成人特发性膜性肾病的表达及其意义[J]. 中华肾脏病杂志，2016, 32(8): 561-567.
|
| [9] |
Hoxha E, Beck LH, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1domain-containing 7a-specific antibodies in membranous nephropathy [J]. J Am Soc Nephrol, 2017, 28(2): 520-531.
|
| [10] |
周雪，钟清，杨渊. THSD7A对特发性膜性肾病诊断效能的Meta分析[J]. 国际泌尿系统杂志，2021, 41(5): 903-908.
|
| [11] |
Liu Y, Zheng S, Ma C, et al. Meta-analysis of the diagnostic efficiency of THSD7A-AB for the diagnosis of idiopathic membranous nephropathy [J]. Glob Chall, 2020, 4(11): 1900099.
|
| [12] |
Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN [J]. Ren Fail, 2018, 40(1): 306-313.
|
| [13] |
王欣，丁国华. THSD7A在特发性膜性肾病中的研究进展[J]. 山东医药，2020, 60(22): 108-111.
|
| [14] |
Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-i domain-containing 7A in Chinese patients with idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(10): 1642-1651.
|
| [15] |
Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up [J]. J Am Soc Nephrol, 2017, 28(1): 348-358.
|
| [16] |
Lin L, Wang WM, Pan XX, et al. Biomarkers to detect membranous nephropathy in Chinese patients [J]. Oncotarget, 2016, 7(42): 67868-67879.
|
| [17] |
张文贤，田梦蕾，赵松，等. 血清PLA2R抗体及THSD7A抗体检测在特发性膜性肾病中的临床意义[J]. 临床荟萃，2018, 33(10): 873-877, 882.
|
| [18] |
Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study [J]. Mod Pathol, 2018, 31(4): 616-622.
|
| [19] |
Vindrieux D, Augert A, Girard CA, et al. PLA2R1 mediates tumor suppression by activating JAK2 [J]. Cancer Res, 2013, 73(20): 6334-6345.
|
| [20] |
Xian L, Dong D, Luo J, et al. Expression of THSD7A in neoplasm tissues and its relationship with proteinuria [J]. BMC Nephrol, 2019, 20(1): 332.
|
| [21] |
Lin F, Zhang D, Chang J, et al. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1 [J]. Eur J Med Genet, 2018, 61(2): 84-88.
|
| [22] |
Zhang Z, Gong T, Rennke HG, et al. Duodenal Schwannoma as a rare association with membranous nephropathy: a case report [J]. Am J Kidney Dis, 2019, 73(2): 278-280.
|
| [23] |
Hou Z, Abudureheman A, Wang L, et al. Expression, prognosis and functional role of THSD7A in esophageal squamous cell carcinoma of Kazakh patients, Xinjiang [J]. Oncotarget, 2017, 8(36): 60539-60557.
|
| [24] |
Stahl PR, Hoxha E, Wiech T, et al. THSD7A expression in human cancer [J]. Genes Chromosomes Cancer, 2017, 56(4): 314-327.
|